RPbio

At a glance

RPbio filed 16 disclosures in the last 12 months.

Revenue for 2025 was ₩136B, up 9.9% on 2024. Operating margin was 3.7% against -0.6% a year earlier. Debt was 46% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩74.9B and operating profit of ₩6.5B.

The 2025 annual report lists 534 employees with an average tenure of 5.6 years and average pay of ₩37.6M, #2127 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩110M each on average. It paid ₩50 per common share in cash dividends. 윤재훈 and related parties held 56.67% at year end.

From the 2025 annual report

Staff: 534 (250 men, 284 women), of whom 195 on fixed-term contracts. Total pay for the year: ₩20.1B. Directors and auditors: 5, paid ₩552M in total.

Dividends (common shares)

Largest shareholder

윤재훈 holds 48.27%; with 5 related parties the group holds 56.67% of common shares at year end (from 59.96% at the start of the year).

Auditor: 현대회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Rankings: Dividend yield #15 of 1,237

Source: 2025 annual business report (DART). How figures are combined

Financial summary